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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic systemic infl ammatory disease with a complex pathogenesis, characterised by synovitis leading to cartilage, tendon and joint destruction. 1 2 Although the pathogenesis of RA is not clear, it is considered to be an immune-mediated infl ammatory disorder, in which the complement system plays an important role.
Recently, cell-derived microparticles (MPs), which are small membrane vesicles released from blood cells or endothelial cells upon activation or during apoptosis, were shown to be associated with complement activation, infl ammation and coagulation in various diseases, including infl ammatory diseases. [3] [4] [5] [6] [7] Although infl ammation causes release of MPs and in turn MPs may induce or enhance infl ammation, it remains unknown whether circulating MPs merely refl ect ongoing infl ammation or whether MPs actually contribute to the disease development.
In vitro studies and animal models indicate that infl ammatory mediators such as tumour necrosis factor α (TNFα) and interleukin (IL)1 trigger MP release. [8] [9] [10] Several other observations, however, suggest a more active role for MPs in development of rheumatoid infl ammatory activity. Leucocyte-derived MPs, present in synovial fl uid of patients with RA, expose tissue factor and trigger coagulation, 11 and induce the production and release of chemokines and cytokines by fi broblastlike synoviocytes, which in turn may further contribute to synovial infl ammation and angiogenesis. 12 Circulating platelet-derived MPs (PMPs) were reported to be elevated in patients with RA, compared to controls, and these PMPs were associated with disease activity as measured by the Disease Activity Score in 28 joints (DAS28). 3 Finally, synovial MPs may also be involved in complement activation in patients with RA, since we recently demonstrated the presence of bound complement components C1q, C3 and C4 as well as complement activator molecules on circulating MPs from patients with RA, further supporting their role in complement activation. 4 To determine whether circulating MP numbers are associated with infl ammatory activity in patients with RA, we compared MPs in patients with very early as yet untreated arthritis and healthy controls. Additionally, we determined the effects of changes in disease activity upon intense anti-infl ammatory therapy with the 'COmBination therapy in Rheumatoid Arthritis' (COBRA) strategy 13 on MP numbers and composition.
METHODS Patients
Consecutive untreated patients with RA (n=24) were included and venous blood was collected at baseline in the fasting state. Of these patients, nine were enrolled in a trial addressing the effects of tight control and intensifi ed COBRA combination treatment in early RA and were treated with COBRA treatment comprising sulfasalazine, methotrexate and high-dose step-down prednisolone at 60 mg/day (week 1), 40 mg/day (week 2), Finally, PBS/calcium (400 μl) was added to each tube and samples were analysed for 1 min on a FACS Calibur device. Data were analysed using Cellquest Pro. 6 All antibodies and control antibodies used were tested and titrated using purifi ed cells and MPs before use.
Identifi cation and characterisation of MPs
MPs were defi ned according to size (forward scatter), side scatter and binding of annexin V, a protein that binds with high affi nity and specifi city to phosphatidylserine, as described previously. 18 It should be mentioned, that the percentage of MPs binding annexin V increases by centrifugation and freeze-thawing. Under these conditions binding of annexin should be considered as a marker to identify MPs rather than refl ecting the exposure of negatively charged phospholipids such as phosphatidylserine. The within-run coeffi cient of variation (CV) is 8% and the dayto-day CV is 13%. The presence of bound complement components (C1q, C3 and C4) as well as bound adapter molecules (CRP, SAP, IgM and IgG) was studied using fl ow cytometry as described previously. 4 
Statistical analysis
Data were analysed with SPSS for Windows V. 16 .0 (SPSS, Chicago, Illinois, USA). According to their distribution, the various parameters are expressed as mean (±SD) or median (interquartile range). Data with a non-Gaussian distribution was log transformed for analysis if possible. To compare the groups, Student t tests or Mann-Whitney U tests were used when appropriate. Furthermore, correlations between variables were analysed by using Pearson correlation or Spearman rho tests. Univariate linear regression analyses were performed on logtransformed data to investigate the infl uence of possible confounders (ie, sex, smoking status, systolic blood pressure and body mass index (BMI) on the results). The Wilcoxon signedrank test was used to investigate the differences in values at baseline and at 8 weeks in the prospectively followed subgroup of patients (n=9). p Values less than 0.05 were considered statistically signifi cant.
RESULTS

Characteristics and infl ammatory measures
Baseline demographic and clinical characteristics of the patients with RA are summarised in table 1. The majority of patients with RA were IgM-rheumatoid factor and/or anti-citrullinated protein antibody (ACPA) positive. Their DAS28 scores (mean 5.2) refl ect patients with a high disease activity. Erythrocyte sedimentation rate (ESR) and CRP levels were signifi cantly elevated in patients compared to controls. The patient group comprised fewer women and had higher systolic blood pressure than the controls. The nine patients prospectively followed had similar ages, BMI levels, systolic blood pressure results and DAS28 scores, but higher CRP (p=0.04) and ESR (p=0.06) levels compared to the other patients with RA (n=15; see tables 1 and 3).
Elevated concentrations of MPs exposing complement components or activator molecules in early RA
The total number of MPs did not differ between patients and controls (table 2) . In patients, the number of MPs exposing C1q, CRP and SAP were signifi cantly elevated compared to controls (table 2 and fi gure 1). These results remained unchanged after adjusting for possible confounders (data not shown).
30 mg/day (week 3), 20 mg/day (week 4), 15 mg/day (week 5), 10 mg/day (week 6) and 7.5 mg/day thereafter. 14 Criteria for inclusion in that study were active disease defi ned by a DAS28 score >3.2. Of these nine patients, an additional fasting blood sample was collected after 8 weeks of treatment. Furthermore, fasting blood was collected from healthy age-matched controls (n=15). All patients fulfi lled the criteria of the American College of Rheumatology (ACR) for RA. 15 All participants gave written informed consent and the study protocol was approved by the Institutional Ethics Committee of the Slotervaart Hospital, Jan van Breemen Institute and BovenIJ Hospital.
Collection of blood samples
Participants were asked to refrain from beverages other than water (particularly no caffeine-containing beverages or alcohol), smoking, medication and meals from midnight prior to the testing day. Blood was collected from the antecubital vein in tubes containing 0.5 ml of 3.2% sodium citrate (BD, San Jose, California, USA). Cells were removed by centrifugation (20 min at 1550 g and 20ºC) within 10 min after collection. Aliquots of cell-free plasma (250 μl) were snap frozen in liquid nitrogen for at least 15 min and stored at −80°C. 16 
Isolation of MPs
MPs were isolated from plasma aliquots (250 μl) after thawing on melting ice by centrifugation (30 min at 18 890 g and 20°C). After centrifugation, MP-free supernatant (225 μl) was removed. The remaining MP pellet was washed with 225 μl phosphatebuffered saline (PBS) containing (0.32% w/v) trisodium citrate (pH 7.4). After centrifugation, the supernatant was removed and the MP pellet was resuspended in PBS-citrate (75 μl).
Labelling of MPs
Aliquots of MPs (5 μl) were diluted in 35 μl of PBS containing 2.5 mmol/litre CaCl 2 (PBS/Ca, pH 7.4). Subsequently, 5 μl allophycocyanin (APC)-labelled annexin V (Caltag Laboratories, Carlsbad, California, USA) was added and combined with either fl uorescein isothiocyanate (FITC)-labelled CD61 (DakoCytomation, Glostrup, Denmark) plus phycoerythrin (PE)-labelled CD62p (P-selectin) or CD63 (glycoprotein 55; both antibodies from Immunotech, Fullerton, California, USA), or FITC-labelled CD144 (Alexis, San Diego, California, USA) plus E-selectin (CD62e-PE; Ancell, Bayport, Minnesota, USA). For appropriate settings of fl uorescence thresholds, MPs were incubated with isotype-matched control antibodies, that is, PE-labelled IgG 1 and/or FITC-labelled IgG 1 (BD), or FITC-labelled Ig (IQP, Groningen, The Netherlands). MPs were labelled for 15 min at room temperature, and labelling was stopped by addition of PBS/calcium (900 μl) to each tube. Samples were analysed for 1 min by fl uorescence-activated cell sorting (FACS) on a FACS Calibur device (BD) and data were analysed using Cellquest Pro (V.4.0.2; BD). 17 Alternatively, MPs (5 μl aliquots) were incubated for 30 min at room temperature with anti-C1q, anti-C3-15, anti-C reactive protein (CRP) 5G4, anti-serum amyloid-P (SAP)-14, anti-IgM, anti-IgG (gift from Sanquin, Amsterdam, The Netherlands) or isotype-matched control antibodies IgG 1 and IgG 2a (Pharmica, Montlingen, Switzerland) in a fi nal volume of 50 μl of PBS containing 2.5 mmol/litre CaCl 2 (PBS/Ca, pH 7.4). After labelling, MPs were washed with PBS/calcium (200 μl). Subsequently, PE-labelled F(ab') 2 and APC-labelled annexin V were added and the mixtures were incubated for 30 min at room temperature. For setting of fl uorescence thresholds, MPs were incubated group.bmj.com on November 24, 2011 -Published by ard.bmj.com Downloaded from At baseline, ESR and CRP signifi cantly correlated with MPs exposing C1q, CRP and SAP (for ESR: r=0.37, p=0.02; r=0.54, p<0.001 and r=0.46, p=0.003, respectively and for CRP: r=0.39, p=0.02; r=0.52, p=0.001 and r=0.36, p=0.02, respectively), confi rming the association between ongoing infl ammation and circulating MPs.
Intense infl ammatory suppression does not alter MP composition
Upon treatment with intense anti-infl ammatory therapy, DAS28, ESR and CRP values decreased signifi cantly (table 3) , but the concentrations of total circulating MPs and MPs exposing complement components or activator molecules were unaffected (table 3, fi gure 2). Numbers of MPs exposing C1q or CRP were still signifi cantly elevated in the patients with RA after treatment compared to controls (data not shown). At 8 weeks we did not fi nd correlations between DAS28 and CRP with total MP numbers or MPs exposing complement components or activator molecules.
DISCUSSION
This study demonstrates that MPs exposing complement components (C1q) or activator molecules (CRP or SAP) are elevated in early active RA. Although a strong anti-infl ammatory therapy using a combination of disease-modifying anti-rheumatic drugs (DMARDs) combined with high-dose prednisolone (under the COBRA scheme 14 ) strongly suppressed infl ammatory activity, circulating MPs were unaffected. Our present data may suggest that infl ammation is not the underlying cause of MP generation in these patients. Imaging studies have shown that synovitis is still apparent in the majority of patients with RA that are clinically in remission, indicating subclinical ongoing infl ammation. 19 The present fi ndings suggest that MPs may be one of the factors that are actively involved in this sustained infl ammation in RA. We cannot exclude, however, that a delay exists between normalisation of systemic infl ammation and circulating MPs or their group.bmj.com on November 24, 2011 -Published by ard.bmj.com Downloaded from composition. Alternatively, subpopulations of circulating MPs may be affected by normalisation of infl ammation rather than the total population of MPs, as assessed in the present study. The biological relevance of MPs or subpopulations thereof to the pathology of early active RA may be questioned given the fact that infl ammation and disease activity were both effi ciently suppressed.
Recently, MPs have emerged as a new proinfl ammatory mediator. In fact, they are thought to amplify or disseminate infl ammation. MPs are thought to trigger infl ammation by several processes such as activation of endothelial cells and leucocytes, triggering production and release of chemokines and cytokines and by activating the complement cascade, which is thought to play a key role in the pathogenesis of RA. 4 12 20-24 By contrast, infl ammation may trigger MP formation. For instance, in vitro studies showed that MPs are released from cells incubated with TNFα or IL1 and a study in mice showed that the number of PMPs in plasma markedly increased upon injection with TNFα. [8] [9] [10] Data from the present study, however, implicate that MPs remain associated with complement activation in early RA despite aggressive anti-infl ammatory therapy.
We cannot answer the question yet as to whether these MPs really have proinfl ammatory properties and thus actively contribute to complement activation, or whether they merely refl ect ongoing complement activation. In the 1980s, Sims and coworkers demonstrated that cells were protected from complement-induced lysis by the release of complement complexenriched MPs. 25 Thus, the presence of elevated concentrations of complement-enriched MPs in early RA may also be a refl ection of ongoing and uncontrolled activation of the complement system.
Our main fi nding that powerful inhibition of infl ammation did reduce disease activity but did not disturb the association between circulating MPs and complement activation, suggests that MPs and complement contribute to the development of and/or the chronic character of infl ammatory diseases such as RA. 
